+1 877 705 1914• 24 / 7
HIPAA Compliant
ISO 27001 Certified

Actively Recruiting

Phase 2
Age: 18Years +
All Genders
ID06186648

Phase 2 Study of Glofitamab with Rituximab or Obinutuzumab Plus CHOP Chemotherapy for Untreated Richter Syndrome

Led by French Innovative Leukemia Organisation · Updated on 2026-06-30

40

Participants Needed

23

Research Sites

78 weeks

Total Duration

AI-Summary

What This Trial Is About

Researchers are investigating a treatment approach for patients with previously untreated Richters syndrome RS, a condition where an aggressive lymphoma develops in individuals with chronic lymphocytic leukemia CLL. This national, multicenter phase 2 trial aims to evaluate the response of RS to a combination therapy involving glofitamab, rituximab or obinutuzumab, and CHOP chemotherapy. The main goal is to determine the percentage of participants achieving a complete response after six cycles of treatment, using established lymphoma response criteria. The study treatment consists of up to eight cycles of 21 days each. In cycle 1, participants receive standard R-CHOP chemotherapy. Cycle 2 involves G-CHOP using obinutuzumab instead of rituximab to reduce cytokine release syndrome risk combined with step-up doses of intravenous glofitamab. Cycles 3 to 6 include R-CHOP plus glofitamab at a fixed dose. If participants show a complete or partial response after cycle 6, they receive two additional infusions of glofitamab alone in cycles 7 and 8. Treatment doses and schedules of chemotherapy drugs and prednisone are carefully defined. Participants undergo thorough screening before treatment, including clinical exams, medical history, blood tests, imaging scans, and biopsies. During treatment, regular assessments monitor clinical status, side effects, blood work, and tumor response using CT and PET scans. Follow-up visits occur every three months for one year after completing treatment or stopping early. The study also includes safety monitoring and long-term survival data collection. Total study duration is about three years, covering enrollment, treatment, and follow-up phases.

CONDITIONS

Brief Title

Evaluation of Treatment by Glofitamab in Combination With Rituximab or Obinutuzumab Plus CHOP in Patients With RIchter Syndrome

Research Team

D

David Schwartz

V

Valérie Rouillé

Not the Right Trial for You?

Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.

Already have an account? Log in here